Search the Newsreel

MarketAxess (MKTX) General Counsel Scott Pintoff Sells 100 Shares

MarketAxess (MKTX) General Counsel Scott Pintoff sold 100 shares at $162.60, part of a pattern of 11 insider sales and zero buys over the past year. Despite this insider selling, MarketAxess is deemed "Significantly Undervalued" by GuruFocus's GF Value model, with a price-to-GF-Value ratio …

Exelon's MidAtlantic Utilities Face Challenges to Serve Data Center Growth

Exelon's MidAtlantic utilities are facing challenges in meeting the increasing demand for power from data centers, an issue that is causing investor concern. This report from Morningstar analyst Andrew Bischof highlights the difficulties for the pure-play electric and gas transmission and distribution utility. Previous …

What’s Behind Xenia Hotels & Resorts (XHR) Stock’s Latest Move?

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

Levi & Korsinsky, LLP has announced an investigation into Exelixis (EXEL) after the company reiterated its full-year 2026 financial guidance on May 5, 2026, only to lower and narrow its revenue outlook weeks later, causing a stock decline. The investigation focuses on whether Exelixis …

MarketAxess (NASDAQ:MKTX) General Counsel Sells $16,260.00 in Stock

MarketAxess General Counsel Scott Pintoff sold 100 shares of MKTX stock for $16,260.00, reducing his total holdings to 11,586 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and declared a quarterly dividend of $0.78 per share. Despite the insider sale, analysts …

Radian Group appoints Deluxe CEO Barry McCarthy to board By Investing.com

Radian Group Inc. has announced the appointment of Barry C. McCarthy, CEO of Deluxe Corporation, to its Board of Directors. McCarthy brings nearly four decades of executive leadership experience in financial services, payments, data, and technology. His appointment is expected to add valuable expertise …

EXELIXIS, INC. SEC Filing (Aug 10, 2026)

This article reports on an SEC Form 144 filing by Exelixis, Inc. (EXEL) on August 10, 2026. The filing indicates a proposed sale of 9,812 shares of common stock with an aggregate market value of $526,496.22, acquired on May 29, 2026, through a restricted …

Crexendo posts investor presentation to website under Regulation FD

Crexendo (CXDO) announced it has posted an investor presentation on its investor relations website, www.crexendo.com

MarketAxess (MKTX) investor files to sell 300 shares after recent sales

Scott Pintoff, an investor in MarketAxess Holdings Inc. (MKTX), has filed a Form 144 notice to sell 300 shares of common stock through Charles Schwab & Co., Inc. The proposed sale date is August 10, 2026, and the shares are related to RSU/PSU equity …

Weekly Recap: ICE to acquire MarketAxess $6B and ADV & OI gains

Intercontinental Exchange, Inc. (ICE) plans to acquire MarketAxess for approximately $6 billion, driven by a significant surge in core trading volumes, with ADV and OI increasing by around 39% and 38% respectively. This growth is largely attributed to gains in interest-rate venues. Additionally, ICE …

Exelon Corp. stock underperforms Monday when compared to competitors

Exelon Corp. (EXC) stock fell 2.43% to $44.50 on Monday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. The company's shares closed 12.14% below their 52-week high of $50.65.

Form 8K Crexendo For: 10 August By Investing.com

This article reports on a Form 8K filing by Crexendo for August 10th. The brief piece includes the company's stock symbol CXDO and its current performance of +2.06%. It also shows general market data for various indices, commodities, bonds, and shares.

Axera Semiconductor Accelerates Edge AI Push as Revenue Surges but Losses Deepen

Axera Semiconductor to Fund Up to RMB70 Million H-Share Awards Buyback

Xeris Biopharma’s Rising Revenue And Wider Losses Could Be A Game Changer For XERS

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average "Buy" rating from nine brokerage firms, with an average 12-month price target of $18.75. Despite insider sales totaling $280,089 over the past three months, institutional investors collectively own 60.67% of the company. The company's stock currently …

(EXEL) as a Liquidity Pulse for Institutional Tactics

This article analyzes Exelixis Inc. (NASDAQ: EXEL) using AI models to provide institutional trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with a significant 26.9:1 risk-reward setup. Three distinct strategies—Position Trading, Momentum Breakout, and Risk Hedging—are detailed, alongside multi-timeframe signal …

Assenagon Asset Management S.A. Has $23.57 Million Stake in Exelon Corporation $EXC

Assenagon Asset Management S.A. significantly increased its stake in Exelon Corporation by 133.9% in the second quarter, bringing its total holdings to 505,564 shares valued at $23.57 million. Despite this, institutional investors collectively own 80.92% of Exelon, while analyst sentiment remains cautious with a …

Brokers Issue Forecasts for XENE Q1 Earnings

Crexendo: Positive Q2 Results And Outlook Could Drive Strong Stock Gains (NASDAQ:CXDO)

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

Quantinno Capital Management LP significantly increased its stake in Xenon Pharmaceuticals Inc. by 125.1% in the first quarter, acquiring an additional 30,816 shares. The biopharmaceutical company, which has no product sales, reported a narrower-than-expected quarterly loss of $1.11 per share. Analyst sentiment remains largely …

Exelon (EXC) Could Be 8% Undervalued Following Second Quarter Earnings

Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results

Xencor, Inc. (NASDAQ:XNCR) recently released a strong quarterly report, with revenue significantly beating expectations and losses being smaller than predicted. This positive performance has led analysts to upgrade their revenue estimates for 2026 and reduce loss estimates, though the consensus price target remains unchanged. …

Crexendo Inc (CXDO) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Crexendo Inc (CXDO), indicating a current earnings forecast score of 8.00 and an average price target of $9.00 based on 6 analysts. Most analysts recommend a "Buy" for CXDO, with an expected revenue of $25.14M for the …

Should Xeris Biopharma Holdings (XERS) Be Revalued After Strong Q2 Revenue And Fresh Guidance?

Xeris Biopharma Holdings (XERS) is attracting investor attention following its Q2 earnings report, which included strong performance and a refined full-year 2026 revenue outlook. The stock is currently trading at $7.93, with a recent 7.74% one-day return, and analysts consider it undervalued with a …

Price to earnings forward of Xenitra Limited – ASX:XEN

Analysts Offer Insights on NA Companies: Fiserv (FISV), X-Energy, Inc. Class A (XE) and Bob’s Discount Furniture, Inc. (BOBS)

This article provides analyst ratings and price targets for three companies: Fiserv (FISV), X-Energy, Inc. Class A (XE), and Bob’s Discount Furniture, Inc. (BOBS). Fiserv received a Hold rating from Cantor Fitzgerald and an average price target of $61.65, while X-Energy, Inc. Class A …

Royal Bank of Canada Has $13.50 Million Stock Position in Deluxe Corporation $DLX

Royal Bank of Canada reduced its stake in Deluxe Corporation by 21.8% in the first quarter, now holding 490,162 shares valued at $13.5 million. Deluxe reported quarterly EPS of $0.87 and revenue of $499.3 million, exceeding analyst estimates, and declared a $0.30 quarterly dividend. …

Exelon Corp (EXC) Stock News Today

This article provides current stock news for Exelon Corp (EXC), an electric utility company. As of August 10th, EXC closed at $44.855, showing a slight increase, with a market capitalization of $46.29 billion. The latest news highlights that GE Vernova Inc stock (GEV) experienced …

FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals reported a net loss of US$110.74 million in Q2 2026, but its successful pre-NDA meeting with the FDA for azetukalner and a US$1.20 billion cash balance position it for potential regulatory milestones. The company is on track to submit an NDA for …

Did Stronger Q2 Earnings and Lowered 2026 Guidance Just Recast Exelixis' (EXEL) Oncology Narrative?

EXELIXIS ($EXEL) announced its Q2 2026 earnings, reporting $0.91 per share, which surpassed estimates. However, the company's revenue of $628.69 million fell short of expectations. Following the announcement, the stock experienced a 5.23% decline.

Xerox (NASDAQ: XRX) swings to Q2 2026 profit as revenue and IP financing grow

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.41. Over the first half of 2026, however, Xencor's …

Xeris Biopharma Holdings Inc (XERS) Stock News Today

This article provides current stock information for Xeris Biopharma Holdings Inc (XERS) including its recent closing price, market capitalization, and P/E ratio. It highlights that the company's stock experienced a gain of 7.74% and indicates that more news and earnings updates are expected soon …

Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside

Xencor, Inc. (XNCR) has seen its average 12-month price target raised from $28.75 to $29 by 12 analysts, implying a 45% potential upside from its Aug. 6 closing price. The consensus rating for the stock remains "Buy" among 14 analysts, with 12 recommending a …

Deluxe Corp (DLX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Deluxe Corp (DLX), highlighting its current earnings forecast score of 8.00 within the Professional & Commercial Services industry. It details analyst ratings, with an average price target of $29.00, and includes expected revenue and EPS for upcoming …